What makes Recursion Pharmaceuticals Inc (RXRX) Stock unique?
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
Recursion Pharmaceuticals Inc (RXRX) Stock is expected to generate profits in the near future
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
A good growth outlook is seen for Recursion Pharmaceuticals Inc (RXRX) Stock by analysts
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
The Recursion Pharmaceuticals Inc (RXRX) Stock expansion path ahead
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
It’s Better to Hope for Prosperity than Become Adversary: Recursion Pharmaceuticals Inc (RXRX) Stock
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
Recursion Pharmaceuticals Inc (RXRX) Stock is more thoughtful than you think
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
Trading Recursion Pharmaceuticals Inc (RXRX) Stock is a good strategy
Morgan Stanley raised the price target for the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock to “an Equal-weight”. The rating was released on May 22, 2023, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $20. The stock was downgraded by BofA Securities, who […]
